240 related articles for article (PubMed ID: 25953645)
1. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes.
Goncalves I; Bengtsson E; Colhoun HM; Shore AC; Palombo C; Natali A; Edsfeldt A; Dunér P; Fredrikson GN; Björkbacka H; Östling G; Aizawa K; Casanova F; Persson M; Gooding K; Strain D; Khan F; Looker HC; Adams F; Belch J; Pinnoli S; Venturi E; Kozakova M; Gan LM; Schnecke V; Nilsson J;
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1723-31. PubMed ID: 25953645
[TBL] [Abstract][Full Text] [Related]
2. Association between renin and atherosclerotic burden in subjects with and without type 2 diabetes.
Gonçalves I; Edsfeldt A; Colhoun HM; Shore AC; Palombo C; Natali A; Fredrikson GN; Björkbacka H; Wigren M; Bengtsson E; Östling G; Aizawa K; Casanova F; Persson M; Gooding K; Gates P; Khan F; Looker HC; Adams F; Belch J; Pinnola S; Venturi E; Kozakova M; Gan LM; Schnecke V; Nilsson J;
BMC Cardiovasc Disord; 2016 Sep; 16(1):171. PubMed ID: 27596252
[TBL] [Abstract][Full Text] [Related]
3. Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Jorsal A; Parving HH; Tarnow L; Theilade S; Rossing P; Schalkwijk CG; Stehouwer CDA
Cardiovasc Diabetol; 2017 Oct; 16(1):139. PubMed ID: 29070037
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study.
Peeters SA; Engelen L; Buijs J; Chaturvedi N; Fuller JH; Schalkwijk CG; Stehouwer CD;
Cardiovasc Diabetol; 2015 Mar; 14():31. PubMed ID: 25848912
[TBL] [Abstract][Full Text] [Related]
5. Impaired fibrous repair: a possible contributor to atherosclerotic plaque vulnerability in patients with type II diabetes.
Edsfeldt A; Gonçalves I; Grufman H; Nitulescu M; Dunér P; Bengtsson E; Mollet IG; Persson A; Nilsson M; Orho-Melander M; Melander O; Björkbacka H; Nilsson J
Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2143-50. PubMed ID: 25035341
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-3 gene polymorphism (rs3025058) affects markers atherosclerosis in type 2 diabetes mellitus.
Pleskovič A; Letonja MŠ; Vujkovac AC; Starčević JN; Caprnda M; Curilla E; Mozos I; Kruzliak P; Prosecky R; Petrovič D
Vasa; 2017 Aug; 46(5):363-369. PubMed ID: 28521653
[TBL] [Abstract][Full Text] [Related]
7. Collagenase matrix metalloproteinase-8 expressed in atherosclerotic carotid plaques is associated with systemic cardiovascular outcome.
Peeters W; Moll FL; Vink A; van der Spek PJ; de Kleijn DP; de Vries JP; Verheijen JH; Newby AC; Pasterkamp G
Eur Heart J; 2011 Sep; 32(18):2314-25. PubMed ID: 21289041
[TBL] [Abstract][Full Text] [Related]
8. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease.
Wu TC; Leu HB; Lin WT; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2005 Sep; 35(9):537-45. PubMed ID: 16128859
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with carotid intima-media thickness and carotid plaques in type 2 diabetic patients.
Cardoso CR; Marques CE; Leite NC; Salles GF
J Hypertens; 2012 May; 30(5):940-7. PubMed ID: 22495135
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease.
Martinez-Aguilar E; Gomez-Rodriguez V; Orbe J; Rodriguez JA; Fernández-Alonso L; Roncal C; Páramo JA
J Vasc Surg; 2015 Feb; 61(2):428-35. PubMed ID: 25441671
[TBL] [Abstract][Full Text] [Related]
11. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan.
Lien LM; Hsieh YC; Bai CH; Chen WH; Chiu HC; Hsieh FI; Shyu KG; Chiou HY; Hsu CY
Atherosclerosis; 2010 Oct; 212(2):595-600. PubMed ID: 20609440
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis.
Montero I; Orbe J; Varo N; Beloqui O; Monreal JI; Rodríguez JA; Díez J; Libby P; Páramo JA
J Am Coll Cardiol; 2006 Apr; 47(7):1369-78. PubMed ID: 16580524
[TBL] [Abstract][Full Text] [Related]
13. Elevated circulating metalloproteinase 7 predicts recurrent cardiovascular events in patients with carotid stenosis: a prospective cohort study.
Moreno-Ajona D; Irimia P; Rodríguez JA; García-Velloso MJ; López-Fidalgo J; Fernández-Alonso L; Grochowitz L; Muñoz R; Domínguez P; Gállego-Culleré J; Martínez-Vila E
BMC Cardiovasc Disord; 2020 Feb; 20(1):93. PubMed ID: 32101136
[TBL] [Abstract][Full Text] [Related]
14. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries.
Johnson JL; George SJ; Newby AC; Jackson CL
Proc Natl Acad Sci U S A; 2005 Oct; 102(43):15575-80. PubMed ID: 16221765
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies against aldehyde-modified collagen type IV are associated with risk of development of myocardial infarction.
Vallejo J; Dunér P; Fredrikson GN; Nilsson J; Bengtsson E
J Intern Med; 2017 Dec; 282(6):496-507. PubMed ID: 28944562
[TBL] [Abstract][Full Text] [Related]
16. Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study.
Shore AC; Colhoun HM; Natali A; Palombo C; Khan F; Östling G; Aizawa K; Kennbäck C; Casanova F; Persson M; Gooding K; Gates PE; Looker H; Dove F; Belch J; Pinnola S; Venturi E; Kozakova M; Goncalves I; Kravic J; Björkbacka H; Nilsson J;
Diabetes Care; 2018 Oct; 41(10):2212-2219. PubMed ID: 30061319
[TBL] [Abstract][Full Text] [Related]
17. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study.
Peeters SA; Engelen L; Buijs J; Jorsal A; Parving HH; Tarnow L; Rossing P; Schalkwijk CG; Stehouwer CDA
Cardiovasc Diabetol; 2017 Apr; 16(1):55. PubMed ID: 28446168
[TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus.
Derosa G; Avanzini MA; Geroldi D; Fogari R; Lorini R; De Silvestri A; Tinelli C; Rondini G; d'Annunzio G
Diabetes Res Clin Pract; 2005 Nov; 70(2):119-25. PubMed ID: 16188574
[TBL] [Abstract][Full Text] [Related]
19. Gene polymorphisms and antigen levels of matrix metalloproteinase-1 in type 2 diabetes mellitus coexisting with coronary heart disease.
Drzewoski J; Sliwińska A; Przybyłowska K; Sliwiński T; Kasznicki J; Zurawska-Klis M; Kosmalski M; Majsterek I
Kardiol Pol; 2008 Oct; 66(10):1042-8; discussion 1049. PubMed ID: 19006025
[TBL] [Abstract][Full Text] [Related]
20. Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy?
van der Zijl NJ; Hanemaaijer R; Tushuizen ME; Schindhelm RK; Boerop J; Rustemeijer C; Bilo HJ; Verheijen JH; Diamant M
Clin Biochem; 2010 May; 43(7-8):635-9. PubMed ID: 20184870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
